There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Elanco Animal Health (ELAN – Research Report) and Insmed (INSM – Research Report) with bullish sentiments.
Elanco Animal Health (ELAN)
Barclays analyst Balaji Prasad maintained a Buy rating on Elanco Animal Health on January 5 and set a price target of $18.00. The company’s shares closed last Friday at $15.45, close to its 52-week high of $15.94.
According to TipRanks.com, Prasad is a 3-star analyst with an average return of
Currently, the analyst consensus on Elanco Animal Health is a Moderate Buy with an average price target of $15.50, implying a 0.3% upside from current levels. In a report issued on January 5, Stifel Nicolaus also maintained a Buy rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
Insmed (INSM)
Barclays analyst Leon Wang maintained a Buy rating on Insmed on January 5 and set a price target of $37.00. The company’s shares closed last Friday at $29.35, close to its 52-week high of $32.00.
Wang has an average return of
According to TipRanks.com, Wang is ranked #2628 out of 8651 analysts.
Currently, the analyst consensus on Insmed is a Strong Buy with an average price target of $44.10, a 52.8% upside from current levels. In a report issued on January 1, Leerink Partners also maintained a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ELAN:
